Pricing for survival

Pricing for survival

As demand for pharmaceutical cost containment intensifies, novel drug-pricing approaches are critical

lifebelt float at the sea

Specialty drug costs are so high that the entire pharmaceutical industry is now under scrutiny for its pricing practices. Although payers and regulators see the need for innovation, there is a much higher onus on drug companies seeking market access to demonstrate the value of their products. 

In this report, we explore the global emerging trends and practical approaches to pricing for value that pharma manufacturers can leverage. We also look at ideas around indication-specific pricing and combination therapies which may be applied in China in future.

© 2024 KPMG Huazhen LLP, a People's Republic of China partnership, KPMG Advisory (China) Limited, a limited liability company in Chinese Mainland, KPMG, a Macau (SAR) partnership, and KPMG, a Hong Kong (SAR) partnership, are member firms of the KPMG global organisation of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved.

The KPMG name and logo are trademarks used under license by the
independent member firms of the KPMG global organisation.

For more detail about the structure of the KPMG global organisation please visit


Connect with us